The FDA recorded a supplemental approval on 8 September 2026 for a generic triamcinolone acetonide product (ANDA 040671) held by Micro Labs.
The record does not state the formulation (triamcinolone acetonide is marketed as injectable, nasal, topical and other forms) or what the supplement changes. Supplements to a generic application usually concern manufacturing, labelling or packaging rather than clinical use.
Nothing here suggests a safety finding or a new indication, and no change in practice follows. Micro Labs is an Indian manufacturer; whether this product or supplement applies to the Indian market is not stated.
- No change to prescribing follows from this supplement.
- Check the product label if your formulary stocks this manufacturer's triamcinolone.
- Continue to monitor for systemic corticosteroid effects with repeated injections.
- Report any quality concern with corticosteroid products through national reporting systems.
Why it matters
Generic corticosteroids are widely used; a supplement is a reason to check labels, not to change practice.
Don't overread it
A licence supplement for a generic is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free